Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > COMMENTARY
COMMENTARY
-
PRTM Shows Results of Investigational Drug Survey
March 14, 2005
-
＜Special Comtribution＞
March 7, 2005
-
＜Special Comtribution＞
March 7, 2005
-
JPMA Update (12)
November 22, 2004
-
JPMA Pudate(11)
November 15, 2004
-
JPMA Update (10)
November 8, 2004
-
JPMA Update (9)
November 1, 2004
-
JPMA Update (8)
October 25, 2004
-
JPMA Update (7)
October 18, 2004
-
JPMA Update (6)
October 11, 2004
-
＜Special Contribution＞
October 4, 2004
-
JPMA Update (5)
October 4, 2004
-
JPMA Update(4)
September 27, 2004
-
JPMA Update (3)
September 20, 2004
-
JPMA Update (2)
September 13, 2004
-
＜New Series＞
September 6, 2004
-
June 7, 2004
-
May 24, 2004
-
BULLETIN
May 24, 2004
-
Brand Equity in the Pharmaceutical Industry
March 8, 2004
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…